iBio Appoints Robert M. Lutz as Chief Financial & Business Officer
16 févr. 2021 08h00 HE
|
iBio, Inc.
BRYAN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the...
iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
09 févr. 2021 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that it will...
iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer
28 déc. 2020 07h30 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the...
iBio Announces Closing of its Public Offering of Common Stock
10 déc. 2020 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing...
iBio Announces Pricing of $35 Million Public Offering of Common Stock
08 déc. 2020 08h55 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the pricing...
iBio Announces Proposed Public Offering of Common Stock
07 déc. 2020 16h01 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 07, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced an...
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
01 déc. 2020 16h30 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”),...
iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
24 nov. 2020 07h30 HE
|
iBio, Inc.
BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the...
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update
16 nov. 2020 16h05 HE
|
iBio, Inc.
BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its...
iBio to Participate in Alliance Global Partners’ Virtual Healthcare Symposium
12 nov. 2020 08h00 HE
|
iBio, Inc.
BRYAN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that...